With the award to Ciechanover, Hershko and Varshavsky, an unfashionable area gets its due. Hershko started investigating protein degradation in the late 1960s, when the emphasis in cell and molecular biology was on the myriad controls that the cell exerts over the creation of proteins. Protein destruction was seen as dull in comparison: a constitutive, largely unregulated process. But protein stabilities vary widely, and Hershko found that the destruction of some proteins required the energy of ATP.
Immature red blood cells were the perfect laboratory for Hershko's investigation of protein destruction. Joined in 1977 by Ciechanover, he broke open the cells and started fractionating.
One of the fractions needed to reconstitute destruction activity retained activity after boiling. Ciechanover and Hershko purified the factor, APF-1, which would later be shown to be identical to a small, previously isolated protein of unknown function called ubiquitin.
The researchers used radioactively labeled ubiquitin to show that multiple copies of ubiquitin were covalently bonded to other proteins prior to the proteins' destruction. They also determined that three enzymes (E1, E2 and E3) were required to execute this linkage.
Ciechanover and Hershko had focussed on cell extracts, so it was left to Varshavsky to establish the importance of the ubiquitin system in living cells. Varshavsky and Ciechanover (then both at the Massachusetts Institute of Technology, Cambridge, Massachusetts) showed that mutant mouse cells that could divide at 32°C but not at 39°C had a defective E1 enzyme, and had lost the ability to destroy short-lived or abnormal proteins.
As the list of proteins targeted by ubiquitin grew, biologists realized that control of protein destruction was as vital as control of protein synthesis. Ubiquitin controls the abundance of cyclins, other cell cycle proteins, p53 (when bound to a human papilloma virus protein), and immune system proteins. Signals on these target proteins are recognized by a family of E3 enzymes; the first of these signals was elucidated by Varshavsky in 1986.
The work of Alter and Houghton made transfusion a less risky proposition. In 1970 the risk of contracting hepatitis from a transfusion was close to 30%. Alter spearheaded an effort to reduce this risk by tracking blood from donor to recipient. Most of the tainted blood, he found, was coming from paid donors, and was often associated with hepatitis B virus infection. By switching to an all-volunteer blood donation system, and instituting hepatitis B testing of donated blood, hepatitis rates were reduced to 10%.
By now hepatitis A virus had also been characterized. But a 'non-A, non-B hepatitis' (NANBH) problem remained. Alter injected blood from NANBH patients into chimpanzees and showed that the animals came down with hepatitis. Fractionation of the blood showed that this transmissible agent was a virus surrounded by a lipid envelope. Alter also raised the profile of NANBH by showing that, despite the mild liver inflammation symptoms, 20% of infected patients developed cirrhosis.
Conventional searches for virus proteins and antibodies to those proteins were proving fruitless in tracking down the causative agent of NANBH. Houghton took a new approach: he extracted DNA and RNA from infected chimpanzees, put the pieces into bacteria so they could drive the production of proteins, and then looked for bacteria producing proteins that bound antibodies from infected, but not uninfected, people. An exhaustive search led to hepatitis C virus, and a blood test that has reduced transfusion-related infection rates to almost zero.
Sydney Brenner won the 1971 Albert Lasker Basic Medical Research Awardfor establishing basic tenets of molecular biology: the existence of messenger RNA (mRNA), the triplet theory and related concepts of translation, and the language of stop codons.
But in the mid-1960s he moved on. "We thought that most of the important problems had been solved", he says. His next target was developmental biology. He searched for an ideal model organism and came up with the roundworm C. elegans. The worm's fixed number of cells, developing in a stereotyped pattern, allowed Brenner and his students to tackle subjects such as cell signaling and apoptosis, and to define an entire wiring diagram for the worm's nervous system. Brenner provided inspiration for the worm genome project, which was completed in 1998.
Meanwhile, Brenner had switched fields again. By the 1990s he was embracing genomics in all its forms. Most recently he has pursued these interests as founder and president of the Molecular Sciences Institute and scientific guru at Lynx Therapeutics, Inc. (Hayward, California), a company using microbeads to do genome-wide scans. Although he has for some years been 'retired', Sydney Brenner is far from idle.
